These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 15310530

  • 1. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.
    Tan LB, Schlosshan D, Barker D.
    Int J Cardiol; 2004 Sep; 96(3):321-33. PubMed ID: 15310530
    [Abstract] [Full Text] [Related]

  • 2. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Sep; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aldosterone receptor antagonism in heart failure.
    Jennings DL, Kalus JS, O'Dell KM.
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone antagonists in congestive heart failure.
    Soberman J, Chafin CC, Weber KT.
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [Abstract] [Full Text] [Related]

  • 6. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC, Pringle S, Struthers A.
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
    Cohn JN, Colucci W.
    Am J Cardiol; 2006 May 22; 97(10A):4F-12F. PubMed ID: 16698330
    [Abstract] [Full Text] [Related]

  • 8. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S, Lindenfeld J, Schrier RW.
    Circ Heart Fail; 2009 Jul 22; 2(4):370-6. PubMed ID: 19808361
    [Abstract] [Full Text] [Related]

  • 9. Aldosterone blockade in heart failure.
    Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 22; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [Abstract] [Full Text] [Related]

  • 10. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction.
    Greenberg B, Zannad F, Pitt B.
    Am J Cardiol; 2006 May 22; 97(10A):34F-40F. PubMed ID: 16698333
    [Abstract] [Full Text] [Related]

  • 11. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U, Wollert KC, Drexler H.
    Cardiovasc Res; 2009 Feb 15; 81(3):519-27. PubMed ID: 19019834
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 15; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 13. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 15; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 14. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 15; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 15. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA.
    Am J Cardiol; 2006 May 22; 97(10A):26F-33F. PubMed ID: 16698332
    [Abstract] [Full Text] [Related]

  • 16. [The significance of aldosterone in chronic heart failure: the RALES study].
    Simko F, Bada V, Simková M, Simko J, Kovács L, Hulín I.
    Vnitr Lek; 2002 Aug 22; 48(8):767-72. PubMed ID: 12425209
    [Abstract] [Full Text] [Related]

  • 17. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS, Morillo CA, Connolly SJ.
    Curr Opin Cardiol; 2005 Jan 22; 20(1):31-7. PubMed ID: 15596957
    [Abstract] [Full Text] [Related]

  • 18. [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure].
    Greco C, Castelli G, Crea F, Gavazzi A, Gensini GF, Scherillo M, Sinagra G.
    G Ital Cardiol (Rome); 2012 Dec 22; 13(12):809-16. PubMed ID: 23196683
    [Abstract] [Full Text] [Related]

  • 19. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones.
    Sun Y, Weber KT.
    Ann Med; 1998 Aug 22; 30 Suppl 1():3-8. PubMed ID: 9800877
    [Abstract] [Full Text] [Related]

  • 20. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.